# Liphorus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liphorus-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Montreal, Canada
- Website: www.liphorus.com
- Total disclosed funding: $6.4M
- Latest round: Series A (Nov 6, 2014)
- Investors on record: 1

## About

Liphorus Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutic solutions to meet healthcare challenges. Their cutting-edge research aims at addressing unmet medical needs, enhancing treatment efficacy, and improving patient outcomes.Founded in 2014, Liphorus Pharmaceuticals is based in Montreal, Canada. The company specializes in developing biopharmaceutical products aimed at improving health outcomes. The firm secured USD 6.4 mn in Series A funding from Sanderling Ventures in November 2014, representing the sole investment round to date. The CEO of Liphorus is Arif Khan, and the company has been structured to focus on delivering specialized treatments since its inception.Liphorus Pharmaceuticals specializes in providing innovative therapeutic solutions designed to address specific health challenges. Their core product offerings include a range of biopharmaceutical therapies that target various medical conditions, enhancing treatment efficacy and patient engagement. These solutions are tailored to meet the needs of healthcare providers and patients, allowing for optimized treatment regimens and improved health outcomes. The products were officially launched within recent years and have since established a client base that includes healthcare institutions across North America and Europe.The company generates revenue primarily through a subscription-based model, wherein clients pay a recurring fee to access their therapeutic solutions and updates. Typical transactions involve healthcare providers entering into annual contracts that ensure continuous access to the necessary treatment tools. The pricing structure accommodates various client needs, resulting in tiered plans that cater to different scales of use and therapeutic options. Flagship products drive significant revenue streams, attracting both direct-to-consumer and B2B clients. Through strategic partnerships with healthcare distributors, the company expands its reach into additional markets, reinforcing its position in the competitive landscape.Liphorus Pharmaceuticals is planning to launch new therapeutic products designed to address additional health conditions, with anticipated release dates aligned with ongoing clinical development timelines. The company aims to expand its presence into European and Asian markets by 2025, focusing on regions with high unmet medical needs. The recent Series A funding of USD 6.4 mn will be utilized to support research and development of these new products as well as to facilitate market entry strategies in the targeted regions.

## Funding rounds

- Series A, Nov 6, 2014, $6.4M — Sanderling Ventures

## Investors

- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series A